Literature DB >> 8258948

Intermittent and continuous exposure to 1,25(OH)2D3 have different effects on growth plate chondrocytes in vitro.

G Klaus1, B König, U Hügel, E Ritz, O Mehls.   

Abstract

Intermittent 1,25(OH)2D3 administration is widely used to suppress parathyroid glands in secondary (renal) hyperparathyroidism. It is unknown whether the effects of continuous and intermittent 1,25(OH)2D3 differ on vitamin D target organs other than parathyroids. Using primary cultures of rat chondrocytes (tibia) we compared the effects of continuous versus intermittent exposure to physiologic concentrations of 1 alpha,25(OH)2D3 on proliferation (radiothymidine incorporation), cell count, protein synthesis ([3H]-leucine incorporation), alkaline phosphatase activity (as a marker of differentiation) and 1 alpha,25(OH)2D3 receptor (VDR) regulation. Cells were synchronized and then exposed for variable periods to a medium containing 10% delipidated FCS and 10(-8) M to 10(-12) M 1 alpha,25(OH)2D3 (or 1 beta,25(OH)2D3 as specificity control). Intermittent (8 hr exposure every 48 hr) as well as continuous (sham washing) administration of 1 alpha,25(OH)2D3 had a biphasic effect on proliferation, that is, stimulation at low (10(-12) M) and inhibition at high (10(-8) M) concentrations. At 10(-12) M intermittent 1 alpha,25(OH)2D3 yielded higher cell counts than continuous 1,25(OH)2D3. This was seen in the log phase, which was day 3 (continuous 141 +/- 2.3% of solvent control; intermittent 185 +/- 2.0%) and in the plateau phase of growth, which was day 6 (128 +/- 2.6 vs. 169 +/- 2.7% of solvent control). Dependence on extracellular Ca is suggested by the effects of varying nominal Ca concentrations in the medium and of Ca channel blockers. Even two hours of exposure to 1 alpha,25(OH)2D3 (10(-12) M) yielded maximal activation of AP during postincubation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258948     DOI: 10.1038/ki.1993.304

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  4 in total

1.  Oral pulse therapy with vitamin D3 for control of secondary hyperparathyroidism.

Authors:  S Feinstein; N Algur; A Drukker
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

2.  Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.

Authors:  G Klaus; A Watson; A Edefonti; M Fischbach; K Rönnholm; F Schaefer; E Simkova; C J Stefanidis; V Strazdins; J Vande Walle; C Schröder; A Zurowska; M Ekim
Journal:  Pediatr Nephrol       Date:  2005-10-25       Impact factor: 3.714

3.  Cyclooxygenases and prostaglandin E2 receptors in growth plate chondrocytes in vitro and in situ--prostaglandin E2 dependent proliferation of growth plate chondrocytes.

Authors:  Christoph Brochhausen; Pia Neuland; C James Kirkpatrick; Rolf M Nüsing; Günter Klaus
Journal:  Arthritis Res Ther       Date:  2006-04-28       Impact factor: 5.156

4.  Intra-Articular Slow-Release Triamcinolone Acetonide from Polyesteramide Microspheres as a Treatment for Osteoarthritis.

Authors:  Anna Tellegen; Martijn Beukers; Imke Rudnik-Jansen; Nicolien van Klaveren; Kan Loi How; Nina Woike; George Mihov; Jens Thies; Erik Teske; Laura Creemers; Marianna Tryfonidou; Björn Meij
Journal:  Pharmaceutics       Date:  2021-03-11       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.